Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits

BMC Veterinary Research

Table 2 Pharmacokinetic parameters of two doses administered SC in 10 New Zealand White Rabbits

PK parameter	Sex	SC 0.05 [mean ± SD (range)]	SC 0.1 [mean ± SD (range)]
AUC_0-t (ng/mL/min)	F	423 ± 149 (285–665)	633 ± 211 (362–863)*
AUC_0-t (ng/mL/min)	M	366 ± 178 (254–632)	958 ± 387 (470–1357)***
AUC_0-∞ (ng/mL/min)	F	634 ± 204 (381–890)	1207 ± 261 (961–1572)***
AUC_0-∞ (ng/mL/min)	M	439 ± 180 (332708)	1093 ± 388 (559–1501)***
C_max (ng/mL)	F	2.6 ± 1.7 (1.0–5.2)	2.5 ± 0.6 (1.8–3.3)
C_max (ng/mL)	M	1.6 ± 0.8 (0.8–2.7)	7.0 ± 3.4 (3.3–11.5)**
Bioavailability (%)	F	48 ± 21 (26–81)	36 ± 14 (20–58)
Bioavailability (%)	M	53 ± 22 (35–82)	71 ± 23 (43–94)**
t_½ (min)	F	315 ± 139 (156–495)	444 ± 185 (305–717)
t_½ (min)	M	192 ± 38 (138–218)	162 ± 31 (130–201)
t_max (min)	F	12 ± 11 (5–30)	14 ± 10 (5–30)
t_max (min)	M	73 ± 81 (5–180)	12 ± 11 (5–30)*

SC subcutaneous, AUC_0-t area under the concentration curve from t0 to t480min, AUC_0-∞ area under the concentration curve from t0 to infinity, C_max maximum concentration, Bioavailability AUC_0-t IM or SC / AUC_0-t IV, t_½ elimination half-life, t_max time at maximum concentration. (*p < 0.05, **p < 0.01. ***p < 0.001 two-way ANOVA with route and sex as independent factors, and animal and treatment day as blocking factors, followed by comparison between the SC 0.05 mg/kg and SC 0.1 mg/kg groups)

ISSN: 1746-6148